syringes or autoinjectors where drug is the PMOA.

PMA/510(k) with Drug Component: Required when device is the PMOA but drug plays a supporting role.

These concepts are central to determining the correct FDA submission pathway for drug-device products.

FDA Submission Models for Drug-Device Products

The FDA recognizes multiple submission models depending on PMOA:

• NDA/BLA with Device Master File Cross-Reference: When the drug or biologic is primary, and the device component is referenced in a device master file.
• PMA/510(k) with Drug Master File Cross-Reference: When the device is primary, referencing drug data as supportive.
• Single Application Model: All data integrated into one application (NDA, BLA, or PMA).
• Separate Application Model: Drug and device submitted separately but reviewed in coordination.
• Request for Designation (RFD): Submitted to OCP to clarify product classification and submission pathway.

Each model requires tailored dossier preparation, regulatory dialogue, and cross-functional coordination.

Processes and Workflow for FDA Drug-Device Submissions

A structured workflow ensures compliance with FDA submission models:

1. Classification: Determine PMOA and file RFD if necessary.
2. Pre-Submission Consultation: Engage with OCP, CDER, CBER, or CDRH to clarify requirements.
3. Dossier Preparation: Develop CTD/eCTD modules for drug/biologic and technical documentation for device.
4. Human Factors Studies: Conduct usability studies to ensure safe self-administration.
5. Regulatory Submission: Submit NDA/BLA, PMA, or 510(k) with cross-referenced master files.
6. Review & Queries: Respond to agency requests from both drug and device divisions.
7. Approval & Launch: Market authorization contingent on compliance with both drug and device requirements.
8. Post-Market Monitoring: Conduct pharmacovigilance and device vigilance activities.

This workflow emphasizes the hybrid nature of FDA drug-device submissions.

Case Study 1: FDA NDA with Device Component

Case: In 2022, FDA reviewed a biologic in a prefilled autoinjector.

• Challenge: Device usability raised concerns about patient error.
• Action: Company conducted additional human factors studies and submitted updated labeling.
• Outcome: FDA approved NDA with device component, requiring post-market vigilance.
• Lesson Learned: Human factors studies are essential in FDA submissions involving self-use devices.

Case Study 2: FDA PMA with Drug Component

Case: A medtech company developed an implantable device delivering an oncology drug.

• Challenge: Integration of drug release kinetics into PMA review.
• Action: Submitted PMA with drug master file cross-reference and bridging pharmacokinetic studies.
• Outcome: FDA approved product after coordinated review between CDRH and CDER.
• Lesson Learned: Cross-center collaboration is crucial for drug-device PMA approvals.

Tools, Templates, and Systems for FDA Submissions

RA professionals use specialized tools to manage drug-device submissions:

• FDA Guidance Documents: Cover combination products, human factors, and device quality considerations.
• Device Master Files (MAFs): Provide technical data referenced in NDA/BLA submissions.
• Electronic Submissions Gateway (ESG): Platform for submitting FDA applications in eCTD format.
• RIM Systems: Track submissions and lifecycle changes across drug and device components.
• Inspection Readiness Templates: SOPs for both GMP and ISO 13485 compliance.

These resources strengthen compliance and streamline the submission process.

Common Challenges and Best Practices

FDA drug-device submissions face multiple challenges:

• Jurisdictional Ambiguity: Determining PMOA can delay development if not clarified early.
• Cross-Center Reviews: Coordinating responses across CDER, CBER, and CDRH requires strong project management.
• Data Integration: Harmonizing drug and device data into one dossier.
• Post-Market Obligations: Meeting dual pharmacovigilance and device vigilance requirements.

Best practices include filing RFDs early, conducting comprehensive human factors studies, using master files strategically, and engaging in pre-submission meetings with FDA centers.

Latest Updates and Strategic Insights

By 2025, FDA submission models reflect new regulatory trends:

• Digital Health Integration: FDA increasingly reviewing apps and sensors as part of combination submissions.
• eCTD 4.0 Adoption: Expanding ability to integrate device data into drug submissions.
• AI-Driven Devices: New guidance anticipated for AI-enabled combination products.
• Global Harmonization: US submission models influencing IMDRF and ICH initiatives for combination products.
• Inspection Focus: FDA inspections increasingly assess both GMP (drug) and QSR/ISO 13485 (device) compliance.

Strategically, RA professionals must integrate cross-center strategies, harmonize submissions, and adopt digital innovations to ensure FDA approval of complex combination products.

Conclusion

FDA drug-device submission models are critical to securing timely approvals for innovative therapies that integrate drugs, biologics, and devices. By mastering PMOA-based pathways, leveraging master files, and aligning with FDA centers, RA professionals can streamline submissions, reduce risks, and accelerate patient access. In 2025 and beyond, hybrid regulatory strategies will dominate combination product approvals, making FDA submission expertise essential for pharma and medtech success.